3 Under-the-Radar Stocks to Buy and Hold
A relatively small group of companies capture much of Wall Street's attention and disproportionately affects the performance of major indexes like the S 500. It's not surprising, then, that many investors seeking attractive stocks naturally turn to these corporations. However, it's possible to find great stocks outside of this small circle. With that in mind, let's consider three companies many investors may not know about but should: Axsome Therapeutics (NASDAQ: AXSM), Madrigal Pharmaceuticals (NASDAQ: MDGL), and (NASDAQ: EXEL). Read on to find out why these under-the-radar stocks may be worth investing in.
Image source: Getty Images.
Axsome Therapeutics is generating strong financial results, thanks in large part to Auvelity, a depression treatment. In the first quarter, the company's revenue increased by 57% year over year to $191.2 million. The great news is that Auvelity recently received a label expansion for the treatment of Alzheimer's disease (AD) agitation. With more than five million patients in the U.S. living with AD agitation and only one previously approved medicine, Axsome Therapeutics is looking at a large opportunity in this niche. And the best part is that the biotech company has several other promising candidates in the pipeline that could, eventually, contribute meaningfully to its financial results.
Source Fool.com
